It has been a while since we have heard anything, but this late in the game I'm half expecting we may not get an update until the quarterly next week.
Few things I am holding my breath for:
1) update on the trial. The last updates we had on this were in early May to say the formulation was completed and the ethics approval for the trial received. Two and half months on and we should certainly have checked off the milestone of "first patient visit"
2) Growth in Pharmacy footprint (and sales). With ~950 pharmacies (making up almost 85% of sales) at the end of Q1, and an agreement with InPharma to utilise their sales force to expand the pharmacy footprint, I am looking forward to seeing a significant uplift in the number of stores covered and some revenue growth along with it.
3) news on product pipeline and distribution deals. Last we heard there were several opportunities in the works for distribution opportunities. We also expect new on some of our own products including development of the Manuka Honey/Hemp products tabled to launch in H2 this year, and formulation of cannabis based skin care range (inc white labels) expected to be commercialised in 2018
4) progress with China expansion (Diagou program) as announced in Q4 last year. Hopefully the Mamacare range is getting some traction there along with the skincare and other natural remedy brands
5) some news on initiatives driven by the new chairman George Livery. A couple of months in now, and having seen posts from George on LinkedIn etc, I am looking forward to seeing some of his expertise from his time a Swisse show through in our strategy/results!
Worst case scenario we should hear sometime in the quarterly update, so shouldnt be much more than a week to wait.
BDA Price at posting:
51.0¢ Sentiment: Buy Disclosure: Held
